Revive Therapeutics

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b StudyJuly 1, 2025
This morning, Beckley Psytech shares topline data from its Phase 2b study of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression (TRD). The study, the largest of the drug to date, printed positive results, with a significant and rapid antidepressant effect and favourable safety profile. Here, we take a closer look at the results and share our quick-take analysis with reference to GH Research’s similar Phase 2b study.
Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 PlansJuly 1, 2025
Psychedelic Alpha’s Josh Hardman sits down with Beckley Psytech CEO Cosmo Feilding-Mellen and Chief Scientific and Medical Officer Rob Conley to discuss today’s topline results from the company’s Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression (TRD).
Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 ReadoutJune 28, 2025
This is the second of a two-part series that looks at how people are reacting to Compass Pathways’ first readout from its Phase 3 program of psilocybin for treatment-resistant depression. Here, we turn to industry reactions.
Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber; Judge Recommends Schedule I Placement for DOI and DOCJune 27, 2025
RFK Jr. Envisages Psychedelics Access ‘Within 12 Months’ • Psychedelics in Washington: FDA, VA, and New Political Signals • Lykos Therapeutics’ New CEO and CMO, Amy Emerson Joins Board • New Zealand Approves First Psilocybin Prescriber • DEA Judge Recommends Schedule I Placement for DOI and DOC • and more…
Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin ResultsJune 25, 2025
It’s been two days since Compass Pathways provided a first look at data from its Phase 3 program, by way of a limited readout from COMP005, a placebo-controlled study of its COMP360 psilocybin in treatment-resistant depression (TRD). Today, we share perspectives from various researchers who commented on the efficacy and safety signals, what they expect from COMP006, and how psilocybin might fare in the real world.

Revive Therapeutics

Latest News

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Ltd. Expands Life Offering to Quebec

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

Join our Newsletter

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights